Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
Neuro Oncol. 2010 Jan;12(1):14-8. doi: 10.1093/neuonc/nop010. Epub 2009 Oct 20.
Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.
双侧听神经鞘瘤是神经纤维瘤病 2 型（NF2）的标志，这些肿瘤损害听力并经常导致耳聋。神经外科干预是唯一公认的治疗方法，但往往会损伤前庭神经。我们报告了 2 例病例，贝伐单抗治疗（一例治疗 3 个月，另一例治疗 6 个月）使进行性听神经鞘瘤退缩超过 40%，并使接受 6 个月治疗的患者的听力显著改善。因此，贝伐单抗治疗可能为 NF2 患者的进行性听神经鞘瘤提供一种有效的治疗方法。
